Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-555-9 | CAS number: 7632-00-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: basic information given
Data source
Reference
- Reference Type:
- publication
- Title:
- Effect of Maternally Administered Sodium Nitrite on Hepatic Erythropoiesis in Fetal CD-1 Mice.
- Author:
- Globus, M., Samuel, D.
- Year:
- 1 978
- Bibliographic source:
- Teratology 18, 367 - 378
Materials and methods
- Principles of method if other than guideline:
- The study was performed to investigate the possible embryotoxic effects of NaNO2 ingested by mammals during pregnancy, and in particular, the influence of NaNO2 on fetal hematopoiesis.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Sodium nitrite
- EC Number:
- 231-555-9
- EC Name:
- Sodium nitrite
- Cas Number:
- 7632-00-0
- Molecular formula:
- HNO2.Na
- IUPAC Name:
- sodium nitrate
- Details on test material:
- sodium nitrite
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- CD-1
- Details on test animals or test system and environmental conditions:
- The animals were maintained on standard rat cubes supplied by Maple Leaf Mills Ltd., Ontario, and tap water ad libitum.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on mating procedure:
- Four- to five-month-old males were mated with 8- to 10-week old females (weighing approximately 22-28 grams) when the latter were found to be in the estrus phase, on the basis of vaginal smears. The day when a vaginal plug appeared was designated day 1 of gestation.
- Duration of treatment / exposure:
- beginning from the 1st day of pregnancy until days 14; 16 or 18 of gestation
- Frequency of treatment:
- one dose/day
- Duration of test:
- until day 19 of gestation
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0.5 mg NaNO2/mouse/day (about 17 mg NaNO2/kg b.w./day)
Basis:
actual ingested
- No. of animals per sex per dose:
- Twenty-three control and 23 treated litters were sacrificed for examination on gestation day 14; 12 control and 9 treated litters were examined on day 16; and four control and four treated litters were evaluated on gestation day 18.
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Duration of test: 14; 16 or 18 days
Examinations
- Fetal examinations:
- Litter size, the number of resorption sites and dead implants, and embryo/fetal weights were recorded at the time of sacrifice. Embryos/fetuses were examined for gross anatomical defects, and, following removal of the livers for analysis, their carcasses were prepared for skeletal examinations. Parameters of erythropoiesis were determined for hepatic tissues, as the liver is the main site of erythrocyte production between gestation days 12 and 19 in
the mouse.
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Details on maternal toxic effects:
No differences were found between treated and control animals, at any of the time points evaluated, for litter size, mean litter weight, mean embryo weight, mean number of resorption sites, or percentages of dead implants. There were no statistically significant differences between treated (n=42) and control (n=37) animals in the frequencies of skeletal abnormalities or variations, but the authors noted a tendency toward talipomanus and talipes in the nitrite-treated group. No data were provided to support this tendency. Hepatic hematopoeisis was evaluated as percentages of total hepatic erythroblasts which were at various distinct stages of maturation. The overall frequency of red blood cells was significantly increased in treated animals at 14 and 16 days of gestation, but not at 18 days. The percentage of mature erythrocytes in hepatic tissue was reduced in treated animals on gestation days 14 and 16, but not on gestationday 18. The percentages of pro- and basophilic erythroblasts were significantly decreased in treated animals of 14 and 16 days gestation age, but not on gestation day 18. Polychromatophilic erythroblasts were significantly more frequent in treated than control animals on gestation day 14, and significantly less frequent on gestation day 16, with no difference between treated and control animals on gestation day 18. Orthochromatophilic erythroblasts were also found at a higher percentage in treated than control animals on gestation day 14, and to be unchanged from controls on gestation day 18. This cell type, however, was found to be more frequent in treated than in control animals on gestation day 16. The overall frequency of white blood cells was slightly, but not significantly, reduced at all three time points. The proportion of neutrophil granulocytes was significantly increased in treated animals at day 18, but was unchanged from control values at the other time points.The authors interpreted their results as indicating a treatment-dependent increase in embryonic hepatic production of erythroid cells. The lack of a sustained increase in mature red blood cells in the livers of day 18 fetuses was considered to be due to a normal developmental shift in the main site of erythropoesis from the liver to the bone marrow and spleen. The authors acknowledge, however, that no increase in red blood cell counts could be demonstrated in the peripheral circulation. Hence the functional significance of their findings remains unclear.
Effect levels (maternal animals)
- Dose descriptor:
- NOAEL
- Basis for effect level:
- other: developmental toxicity
- Remarks on result:
- not determinable
- Remarks:
- no NOAEL identified
Results (fetuses)
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Fetal Effects
No significant differences between groups for: litter size, weight, resorptions, fetal death, or skeletal abnormalities or variations.
Significant changes in hepatic erythropoiesis.
No sustained increase in hepatic mature red blood cells on day 18.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.